Naveen M Kulkarni1, Daniella F Pinho2, Srikala Narayanan3, Avinash R Kambadakone4, Jeremy S Abramson5, Dushyant V Sahani4. 1. 1 Division of Abdominal Imaging, Medical College of Wisconsin, Milwaukee, WI. 2. 2 University of Texas Southwestern Medical Center, Dallas, TX. 3. 3 Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA. 4. 4 Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, 55 Fruit St, White 270, Boston, MA 02114. 5. 5 Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
OBJECTIVE: The purpose of this article is to examine the role of different imaging biomarkers, focusing in particular on the use of updated CT and PET response criteria for the assessment of oncologic treatment effectiveness in patients with lymphoma but also discussing other potential functional imaging methods and their limitations. CONCLUSION: Lymph nodes are commonly involved by metastatic solid tumors as well as by lymphoma. Evolving changes in cancer therapy for lymphoma and metastases have led to improved clinical outcomes. Imaging is a recognized surrogate endpoint that uses established criteria based on changes in tumor bulk to monitor the effects of treatment. With the introduction of targeted therapies and novel antiangiogenic drugs, the oncologic expectations from imaging assessment are changing to move beyond simple morphologic methods. Molecular and functional imaging methods (e.g., PET, perfusion, DWI, and dual-energy CT) are therefore being investigated as imaging biomarkers of response and prognosis. The role of these advanced imaging biomarkers extends beyond measuring tumor burden and therefore might offer insight into early predictors of therapeutic response. Despite the potential benefits of these exciting imaging biomarkers, several challenges currently exist.
OBJECTIVE: The purpose of this article is to examine the role of different imaging biomarkers, focusing in particular on the use of updated CT and PET response criteria for the assessment of oncologic treatment effectiveness in patients with lymphoma but also discussing other potential functional imaging methods and their limitations. CONCLUSION: Lymph nodes are commonly involved by metastatic solid tumors as well as by lymphoma. Evolving changes in cancer therapy for lymphoma and metastases have led to improved clinical outcomes. Imaging is a recognized surrogate endpoint that uses established criteria based on changes in tumor bulk to monitor the effects of treatment. With the introduction of targeted therapies and novel antiangiogenic drugs, the oncologic expectations from imaging assessment are changing to move beyond simple morphologic methods. Molecular and functional imaging methods (e.g., PET, perfusion, DWI, and dual-energy CT) are therefore being investigated as imaging biomarkers of response and prognosis. The role of these advanced imaging biomarkers extends beyond measuring tumor burden and therefore might offer insight into early predictors of therapeutic response. Despite the potential benefits of these exciting imaging biomarkers, several challenges currently exist.
Entities:
Keywords:
DWI; International Working Group criteria; Lugano criteria; PET; lymphoma
Authors: Valentina Brancato; Marco Aiello; Roberta Della Pepa; Luca Basso; Nunzia Garbino; Emanuele Nicolai; Marco Picardi; Marco Salvatore; Carlo Cavaliere Journal: Diagnostics (Basel) Date: 2020-09-16